Trial: 201902046

An Open Label, Expanded Access Protocol Using 131I-Metaiodobenzylguanidine (131I-MIBG) Therapy In Patients With Refractory High-Risk Neuroblastoma, Pheochromocytoma, OR Paraganglioma (not eligible for approved treatment)

Phase

N/A

Principal Investigator

Huang, Frederick

Disease Site

Brain and Nervous System

Learn more about this study at: clinicaltrials.gov